Home > Insider Trading > Filing (0000939767-24-000030)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
939767	Exelixis Inc.	EXEL	Biological Products, (No Disgnostic Substances) (2836)	043257395

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1692954	J. Patrick Haley	C/O Exelixis, Inc. 1851 Harbor Bay Parkway Alameda CA 94502	Evp, Commercial	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-02-23	63,350	$0.00	431,886	No	4	A	Direct
Common Stock	Disposition	2024-02-23	47,020	$21.45	384,866	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	23,539	Indirect	By spouse
Common Stock	10,648	Indirect	By 401(k)

Footnotes

Represents shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.
The restricted stock units were granted to the Reporting Person on the Transaction Date pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan. The restricted stock units will vest as to 1/4th of the originalnumber of shares subject to the restricted stock unit award on May 15, 2025 and thereafter as to 1/4th of the original number of shares subject to the restricted stock unit award on each May 15th until fully vested.
Includes 300,823 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Represents the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $21.44 to $21.48. Reporting Person undertakes to provide Exelixis, Inc., any security holder of Exelixis, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote 4 to this Form 4.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of February 22, 2024.